Clearance and phenotype of extracellular vesicles after red blood cell transfusion in a human endotoxemia model

Manen, Lisa van; Peters, Anna; Sluijs, P. Matthijs van der; Nieuwland, Rienk; Bruggen, Robin van; Juffermans, Nicole P.

doi:10.1016/j.transci.2019.05.008

Cited by 9 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RBCs have been associated to activation of coagulation (Biró et al, 2003;Burger et al, 2013;Rubin et al, 2013), endothelial activation (Straat et al, 2016b) and immunomodulation (Danesh et al, 2014;Straat et al, 2016a), and thus could be involved in side effects that occur after blood transfusion (Danesh et al, 2014;van Manen et al, 2019). In contrast with EVs produced by circulating RBCs, EVs produced during RBC storage do not have detectable levels of membrane markers associated with clearance, except for phosphatidylserine which was exposed in low amount by a small fraction of EVs (van Manen et al, 2019).…”

Section: Cellular Uptake Of Evsmentioning

confidence: 99%

Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles

Borgheti-Cardoso

Kooijmans

Chamorro

et al. 2020

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Cellular Uptake Of Evsmentioning

confidence: 99%

Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles

Borgheti-Cardoso

Kooijmans

Chamorro

et al. 2020

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Different source cells can be used for camouflage nanodrugs, including red blood cells (RBCs), platelets, bacteria, cancer cells (CCs), stem cells (SCs), and white blood cells (WBCs), which are coated onto nanodrugs by co-extrusion, extrusion/sonication, freeze-thaw/sonication, extrusion/sonication and stirring, and more ( Choi et al, 2020 ). In this review, we focus on a cell membrane-wrapped nanodrug delivery system, and will detailly introduce the types of various cell membrane and their mechanism and difference in application ( Labernadie et al, 2017 ; van Manen et al, 2019 ; Wang et al, 2019 ; Zhao et al, 2021b ; Harris et al, 2022 ; Kong et al, 2022 ; Wu et al, 2022 ; Chen et al, 2023 ) ( Figure 5 ; Table 5 ).…”

Section: The Types and Applications Of Cell Membrane Camouflage On Na...mentioning

confidence: 99%

“…Platelet is another popular type of blood cell and chosen for extracting cell membranes to camouflage nanodugs ( Zhang et al, 2018 ). Similar to RBCM ( Zou et al, 2019 ), PM has an inherent immune escaping ability attributed to the CD47 and CD59 protein in PM sending “do not eat me” signals to immune cells ( van Manen et al, 2019 ; Wang et al, 2019 ). Advanced to RBCM, PM has specifically cancer-targeting ability attributed to the overexpression of P-selectin, which allows PM-cloaked nanodrug to selectively bind to the CD44 receptors upregulated on the surface of cancer cells ( Wang et al, 2019 ).…”

Section: The Types and Applications Of Cell Membrane Camouflage On Na...mentioning

confidence: 99%

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Liu,

Yu,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Hematologic malignancies (HMs), also referred to as hematological or blood cancers, pose significant threats to patients as they impact the blood, bone marrow, and lymphatic system. Despite significant clinical strategies using chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, or immunotherapy, the five-year overall survival of patients with HMs is still low. Fortunately, recent studies demonstrate that the nanodrug delivery system holds the potential to address these challenges and foster effective anti-HMs with precise treatment. In particular, cell membrane camouflaged nanodrug offers enhanced drug targeting, reduced toxicity and side effects, and/or improved immune response to HMs. This review firstly introduces the merits and demerits of clinical strategies in HMs treatment, and then summarizes the types, advantages, and disadvantages of current nanocarriers helping drug delivery in HMs treatment. Furthermore, the types, functions, and mechanisms of cell membrane fragments that help nanodrugs specifically targeted to and accumulate in HM lesions are introduced in detail. Finally, suggestions are given about their clinical translation and future designs on the surface of nanodrugs with multiple functions to improve therapeutic efficiency for cancers.

show abstract

“…However, REVs also induce strong host responses with production of TNF, IL-6, and IL-8 [ 16 ]. Therefore, REVs are closely associated with adverse effects of blood transfusion [ 17 , 18 ]. In addition, REVs are involved in pathological processes, including Parkinson’s disease.…”

Section: Extracellular Vesicles Derived From Erythrocytesmentioning

confidence: 99%

Blood cell-derived extracellular vesicles: diagnostic biomarkers and smart delivery systems

Liang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are released by most of the cells or tissues and act as nanocarriers to transfer nucleic acids, proteins, and lipids. The blood system is the most abundant source of extracellular vesicles for purification, and it has attracted considerable attention as a source of diagnostic biomarkers. Blood-derived extracellular vesicles, especially vesicles released from erythrocytes and platelets, are highly important in nanoplatform-based therapeutic interventions as potentially ideal drug delivery vehicles. We reviewed the latest research progress on the paracrine effects and biological functions of extracellular vesicles derived from erythrocytes, leukocytes, platelets, and plasma. From a clinical perspective, we summarize selected useful diagnostic biomarkers for therapeutic intervention and diagnosis. Especially, we describe and discuss the potential application of erythrocyte-derived extracellular vesicles as a new nano-delivery platform for the desired therapeutics. We suggest that blood-derived extracellular vesicles are an ideal nanoplatform for disease diagnosis and therapy.

show abstract

Clearance and phenotype of extracellular vesicles after red blood cell transfusion in a human endotoxemia model

Cited by 9 publications

References 24 publications

Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles

Extracellular vesicles derived from Plasmodium-infected and non-infected red blood cells as targeted drug delivery vehicles

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Blood cell-derived extracellular vesicles: diagnostic biomarkers and smart delivery systems

Contact Info

Product

Resources

About